IPP Bureau
Kaneka Covid-19 kits detect all four variants simultaneously
By IPP Bureau - October 11, 2021
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
By IPP Bureau - October 11, 2021
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Sai Life Sciences presents its midterm report
By IPP Bureau - October 11, 2021
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
AstraZeneca India launches solar project to achieve sustainability goals
By IPP Bureau - October 11, 2021
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Gland Pharma receives tentative nod for Sugammadex injection
By IPP Bureau - October 09, 2021
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis
By IPP Bureau - October 09, 2021
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Roche’s Alzheimer antibody granted U.S. FDA Breakthrough Therapy Designation
By IPP Bureau - October 09, 2021
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Tezepelumab granted Orphan Drug Designation in the US
By IPP Bureau - October 09, 2021
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Govt clarifies on export ban of syringes
By IPP Bureau - October 09, 2021
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
Alnylam partners with the Medicines Manufacturing Innovation Centre
By IPP Bureau - October 09, 2021
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
ASU drug manufacturing licence goes online
By IPP Bureau - October 09, 2021
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
Sanofi says positive results from flu vaccine with mRNA booster study
By IPP Bureau - October 08, 2021
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
Cigna sells its life, accident and allied businesses to Chubb for US $ 5.75 billion
By IPP Bureau - October 08, 2021
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
CDSCO approves Syntellix implants
By IPP Bureau - October 08, 2021
This opens up a huge market for the company’s Magnezis implants in India
Lilac Insights launches mental health platform AtEase
By IPP Bureau - October 08, 2021
The platform will provide a safe and nurturing space for women, and non-binary individuals
